Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Anemia
Beta Thalassemia

Interventions

RADIATION: TBI
DRUG: Hydroxyurea
BIOLOGICAL: briquilimab
DRUG: Filgrastim (G-CSF)
DRUG: Sirolimus
BIOLOGICAL: Alemtuzumab
DRUG: Plerixafor

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)